Literature DB >> 24420081

Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

V Drinovac1, L Bach-Rojecky, Z Lacković.   

Abstract

The mechanism of botulinum toxin type A (BTX-A) antinociceptive action in the central nervous system is little known. The potential interaction between BTX-A and GABAergic system has not been investigated previously. In the present study, we demonstrate prevention of BTX-A antinociceptive effect on formalin-induced inflammatory pain and partial sciatic nerve transection-induced mechanical allodynia by GABA-A antagonist bicuculline, thus suggesting association of the GABA-A receptors and antinociceptive action of BTX-A.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24420081     DOI： 10.1007/s00702-013-1150-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  23 in total

Review 1.  The synaptic split of SNAP-25: different roles in glutamatergic and GABAergic neurons?

Authors:  M Matteoli; D Pozzi; C Grumelli; S B Condliffe; C Frassoni; T Harkany; C Verderio
Journal:  Neuroscience       Date:  2008-03-20       Impact factor: 3.590

2.  Comparison of the analgesic effects of various opioid peptides by a newly devised intracisternal injection technique in conscious mice.

Authors:  H Ueda; H Amano; H Shiomi; H Takagi
Journal:  Eur J Pharmacol       Date:  1979-06-15       Impact factor: 4.432

3.  The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action.

Authors:  A Micov; M Tomić; B Popović; R Stepanović-Petrović
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

4.  Partial sciatic nerve transection as a model of neuropathic pain: a qualitative and quantitative neuropathological study.

Authors:  Thies Lindenlaub; Claudia Sommer
Journal:  Pain       Date:  2000-12-15       Impact factor: 6.961

Review 5.  Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.

Authors:  K Roger Aoki; Joseph Francis
Journal:  Parkinsonism Relat Disord       Date:  2011-11       Impact factor: 4.891

6.  Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection.

Authors:  Lidija Bach-Rojecky; Melita Salković-Petrisić; Zdravko Lacković
Journal:  Eur J Pharmacol       Date:  2010-02-01       Impact factor: 4.432

Review 7.  Pre- and postsynaptic inhibitory control in the spinal cord dorsal horn.

Authors:  Rita Bardoni; Tomonori Takazawa; Chi-Kun Tong; Papiya Choudhury; Gregory Scherrer; Amy B Macdermott
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

8.  Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models.

Authors:  Christine Favre-Guilmard; Michel Auguet; Pierre-Etienne Chabrier
Journal:  Eur J Pharmacol       Date:  2009-07-01       Impact factor: 4.432

Review 9.  Future aspects of botulinum neurotoxins.

Authors:  K R Aoki
Journal:  J Neural Transm (Vienna)       Date:  2007-06-08       Impact factor: 3.575

10.  Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy.

Authors:  Boris Filipović; Ivica Matak; Lidija Bach-Rojecky; Zdravko Lacković
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240
View more
  10 in total

Review 1.  Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors:  Till Sprenger; M Viana; C Tassorelli
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 2.  Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.

Authors:  P Barbanti; G Egeo; L Fofi; C Aurilia; S Piroso
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

3.  Subcutaneous BoNT/A Injection for Intractable Pain and Disability in Complex Regional Pain Syndrome: A Case Report.

Authors:  Yan Tereshko; Chiara Dalla Torre; Christian Lettieri; Enrico Belgrado; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Toxins (Basel)       Date:  2022-06-16       Impact factor: 5.075

4.  Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain.

Authors:  V Drinovac Vlah; L Bach-Rojecky; Z Lacković
Journal:  J Neural Transm (Vienna)       Date:  2016-08-09       Impact factor: 3.575

Review 5.  Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception.

Authors:  Dong-Wan Kim; Sun-Kyung Lee; Joohong Ahnn
Journal:  Toxins (Basel)       Date:  2015-06-30       Impact factor: 4.546

6.  Impact of Botox-A SNAP-25 protein expression and the mechanism of inhibitory neurotransmitter imbalance in chronic sciatic nerve pain rat model.

Authors:  Xu-Dong Ding; Wei Wang; Zhi-Gang Ding; Yan-Ping Liu; Jing Zhong; Hua-Xian Chen
Journal:  Exp Ther Med       Date:  2017-04-18       Impact factor: 2.447

7.  A preliminary trial of botulinum toxin type A in patients with vestibular migraine: A longitudinal fMRI study.

Authors:  Sun-Young Oh; Jin-Ju Kang; Sohui Kim; Jong-Min Lee; Ji-Soo Kim; Marianne Dieterich
Journal:  Front Neurol       Date:  2022-07-25       Impact factor: 4.086

8.  Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.

Authors:  Rezvan Rostami; Shivam Om Mittal; Reza Radmand; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2016-01-13       Impact factor: 4.546

9.  Botulinum toxin type A enhances the inhibitory spontaneous postsynaptic currents on the substantia gelatinosa neurons of the subnucleus caudalis in immature mice.

Authors:  Seon-Hui Jang; Soo-Joung Park; Chang-Jin Lee; Dong-Kuk Ahn; Seong-Kyu Han
Journal:  Korean J Physiol Pharmacol       Date:  2018-08-27       Impact factor: 2.016

Review 10.  Mechanisms of Botulinum Toxin Type A Action on Pain.

Authors:  Ivica Matak; Kata Bölcskei; Lidija Bach-Rojecky; Zsuzsanna Helyes
Journal:  Toxins (Basel)       Date:  2019-08-05       Impact factor: 4.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.